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Abstract: End-stage renal disease (ESRD) is the final stage of chronic kidney disease, which is
increasingly prevalent worldwide and is associated with the progression of cardiovascular disease
(CVD). Indoxyl sulfate (IS), a major uremic toxin, plays a key role in the pathology of CVD via adverse
effects in endothelial and immune cells. Thus, there is a need for a transcriptomic overview of IS
responsive genes in immune cells of ESRD patients. Here, we investigated IS-mediated alterations in
gene expression in monocytes from ESRD patients. Transcriptomic analysis of ESRD patient-derived
monocytes and IS-stimulated monocytes from healthy controls was performed, followed by analysis
of differentially expressed genes (DEGs) and gene ontology (GO). We found that 148 upregulated and
139 downregulated genes were shared between ESRD patient-derived and IS-stimulated monocytes.
Interaction network analysis using STRING and ClueGo suggests that mainly metabolic pathways,
such as the pentose phosphate pathway, are modified by IS in ESRD patient-derived monocytes.
These findings were confirmed in IS-stimulated monocytes by the increased mRNA expression of
genes including G6PD, PGD, and TALDO1. Our data suggest that IS causes alteration of metabolic
pathways in monocytes of ESRD patients and, thus, these altered genes may be therapeutic targets.
Keywords: end-stage renal disease (ESRD); monocytes; uremic toxins; indoxyl sulfate (IS);
aryl hydrocarbon receptor; transcriptomic analysis; metabolic pathway
Key Contribution: Comparative transcriptomic analysis between ESRD patient-derived monocytes
and indoxyl sulfate (IS)-stimulated monocytes reveals that IS contributes to alteration of several
metabolic pathways in monocytes of ESRD patients. Furthermore, this analysis identifies potentially
important targets in the progression of CVD in CKD.
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1. Introduction
Chronic kidney disease (CKD) is a prevalent disease of increasing frequency worldwide. Based on
the estimated glomerular filtration rate (eGFR), CKD is categorized into five stages [1] and patients
diagnosed with the final stage, stage 5 (eGFR < 15 mL/min) also known as end-stage renal disease
(ESRD), require hemodialysis or kidney transplantation. Despite the advance of current therapeutic
technologies, the mortality rate of ESRD patients has reached 20% [2]. The main causes of morbidity and
mortality of patients with ESRD are cardiovascular diseases (CVD) and infections, with mortality rates
of 50% and 20%, respectively [3,4]. Classical risk factors of CVD including diabetes, dyslipidemia and
high blood pressure, cannot entirely account for the increased cardiovascular risk in ESRD patients [5,6].
In addition, the control of traditional risk factors, such as obesity, hypertension, and cholesterol as well
as treatments such as statins for CVD, only show partial protection from cardiovascular events [5,7–9].
Based on this fact, it is assumed that other factors are important in the progression of CVDs in
ESRD patients.
Progressive renal failure in CKD causes the accumulation of uremic toxins, which is intimately
associated with high cardiovascular risk and mortality due to oxidative stress and augmented cytokine
milieu caused by these molecules [10,11]. Among approximately 100 uremic toxins identified so far
in patients with CKD [10], indoxyl sulfate (IS) and p-cresyl sulfate (PCS), tryptophan and tyrosine
derivatives, respectively, are major uremic toxins derived from gut microbiota and are metabolized via
microbial fermentation. In ESRD patients, the elevated risk of CVD is closely related to uremia-related
immune activation, for instance, hypercytokinemia and inflammation [12–14]. IS and PCS are
also well-known inducing factors of inflammatory cytokine and chemokine production in vascular
endothelial cells (VECs) and vascular smooth muscle cells (VSMCs). A hallmark of CKD-related CVD
is intravascular macrophage and T-cell mediated inflammation [15]; however, uremic toxin-mediated
immune dysfunctions are poorly understood. Our previous study suggested that IS-induced TNF-α
production by monocytes in ESRD patients causes endothelial damage through the recruitment and
expansion of the cytotoxic CD4+CD28− T cell population [16]. Moreover, IS-induced TNF-α production
in human macrophages is intricately regulated by crosstalk between the aryl hydrocarbon receptor
(AhR), NF-κB, and SOCS2. Likewise, IS-activated macrophages also contribute to the progression of
atherosclerosis by induction of proinflammatory cytokines via Notch signaling [17].
Transcriptome analysis enables the identification of potential pathogenic drivers of disease and
biological targets for treatment [18]. Despite accumulating evidence that monocytes/macrophages
play a pivotal role in the pathogenesis of CVD in ESRD patients, current knowledge of transcriptomic
signatures of monocytes or macrophages in ESRD patients is lacking, and data, if any, comes mainly from
analysis of the average gene expression in bulk peripheral blood mononuclear cells (PBMC)s [19–22].
Moreover, little is known about how much the major uremic toxins, IS and PCS, affect gene expression
in monocytes of ESRD and CKD patients.
In the present study, we sought to unveil alterations in gene expression and biological pathways
mediated by major uremic toxins, such as IS and PCS, in ESRD patient-derived monocytes via
microarray and interaction network analysis.
2. Results
2.1. Transcriptomic Analysis of Monocytes Derived from ESRD Patients and Monocytes Stimulated with Major
Uremic Toxins, IS and PCS
CKD is associated with significant increases in CVDs including atherosclerosis, the development
of which occurs as a result of the local inflammatory milieu and resulting effects on the arterial wall [6].
Further, retained uremic toxins are believed to be an underlying cause of the proinflammatory cytokine
milieu and concomitantly impaired immune system seen in CKD. Our previous study demonstrated
that in ESRD patients, monocytes respond to IS through the AhR and consequently produce increased
levels of TNF-α. Given the critical role of monocytes in the pathogenesis of CKD, it is important
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to understand uremic toxin-mediated changes in gene expression in monocytes. To investigate the
alteration of gene expression in monocytes derived from ESRD patients, we performed microarray
analysis on freshly purified monocytes from peripheral blood of three ESRD patients and three healthy
controls (HCs). The demographic characteristics of ESRD patients are presented in Supplementary
Table S1. As a result, we identified differentially expressed genes (DEGs) including 3164 upregulated
genes and 3466 downregulated genes in ESRD patient-derived monocytes compared to HCs (p < 0.05,
FDR < 0.25). Further analysis to compare the transcriptomic profiles of the two groups using heatmaps,
volcano plots, and principle component analysis (PCA) (Figure 1A–C) clearly illustrate the substantial
amount of transcriptomic alterations in ESRD patient-derived monocytes compared to those of HCs.
Thus, this suggests that these changes are potentially attributable to the chronic exposure to uremic
toxins. IS and PCS, which originate from dietary amino acid metabolites of colonic microbial organisms,
are the two most problematic uremic toxins, conferring renal and cardiovascular toxicity by increased
inflammation, calcification, and oxidative stress [11,23–25]. To explore uremic toxin-related changes in
gene expression in ESRD patient-derived monocytes, purified monocytes from healthy controls were
treated with IS or PCS for 24 h followed by microarray analysis of these samples. DEGs in IS-stimulated
monocytes consist of 713 upregulated and 886 downregulated genes compared to control monocytes
(Figure 1D–F). Of interest, a limited range of transcriptomic changes was observed in PCS-stimulated
monocytes (138 upregulated and 132 downregulated genes) as shown in the heatmap, volcano plot,
and PCA (Figure 1D–F), implying that altered gene expression in ESRD patient-derived monocytes is
associated more with the effects of IS than PCS. Furthermore, these results suggest that the uremic
milieu is related to the alteration of the transcriptomic profile in ESRD patient-derived monocytes.
Figure 1. Cont.
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Figure 1. Transcriptomic profiles in End-Stage Renal Disease (ESRD) patient-derived monocytes and
indoxyl sulfate (IS)- or p-cresyl sulfate (PCS)-stimulated monocytes derived from healthy controls
(HCs). (A–C), The CD14+ monocytes were separated from ESRD and HC patient peripheral blood
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mononuclear cells (PBMCs) using magnetic beads (n = 3). Total RNA was purified and analyzed by
microarray. Heatmap (A), volcano plot (B), and principle component analysis (PCA) (C) are presented.
(D,E), Monocytes separated from HCs were treated with IS 1000 µM or PCS 500 µM for 24 h (n = 3),
and then purified total RNA was subjected to microarray analysis. Heatmap of differentially expressed
genes (DEGs) (D), volcano plot (E), and PCA (F) were analyzed among IS-treated, PCS-treated, and
control (Con) monocytes.
2.2. Common Differentially Expressed Genes (DEGs) between ESRD Patient-Derived Monocytes and
IS-Stimulated Monocytes
To further elucidate IS-mediated alteration of gene expression in ESRD patient-derived monocytes,
we conducted a comparative analysis using Venn diagrams which allows for identification of the
number of shared differentially expressed genes (DEGs) among ESRD-patient derived monocytes, IS- or
PCS-treated monocytes (Figure 2A). This revealed that 148 upregulated and 139 downregulated genes
were shared DEGs between ESRD patient-derived monocytes and IS-treated monocytes (Figure 2).
Only 25 genes out of 270 DEGs in monocytes treated with PCS were shared with DEGs in ESRD
patient-derived monocytes (Figure 2A), suggesting a minimal effect of PCS on regulating transcriptional
levels in monocytes of ESRD patients. Our preliminary study also showed no notable impact on
production of proinflammatory cytokines such as TNF-α and IL-1β in PCS-treated monocytes compared
with IS-treated monocytes, although both uremic toxins accumulate significantly in the plasma of
ESRD patients [16]. Thus, we decided to focus our analysis on the effects of IS on the alteration of gene
expression in monocytes and its putative roles in ESRD patient-derived monocytes. Expression profiling
of a total of 287 shared genes between DEGs in monocytes derived from ESRD patients and IS-treated
monocytes was visualized as heatmaps (Figure 2B) and major shared genes were listed according
to the log fold change in monocytes of patients with ESRD compared to HCs (Table 1 and Table S2).
As reported in our previous study, representatively upregulated genes in the top 50 (Table 1) included
CYP1B1, a typical AhR-responsive and xenobiotic metabolism-related gene, and TNF-α, a major
proinflammatory cytokine produced by IS-treated monocytes. This data suggests that our microarray
analysis fairly reflects the changes in gene expression in ESRD patients in the uremic toxin-rich milieu.
Our results show that the number of DEGs shared with ESRD patient-derived monocytes is higher
in IS-stimulated monocytes than in those stimulated with PCS. Thus, this implies that IS is a major
uremic toxin involved in alteration of gene expression in ESRD patient-derived monocytes.
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Figure 2. Differentially expressed genes (DEGs) common between ESRD patient-derived monocytes
and IS- or PCS-stimulated monocytes derived from HCs. (A), Comparative analysis using Venn
diagrams to identify the number of shared DEGs among those (p < 0.05, FDR < 0.25) obtained from each
microarray analysis. (B), Heatmap of 148 upregulated and 139 downregulated shared DEGs between
ESRD patient-derived monocytes and IS-stimulated monocytes shown in (A).
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Table 1. Upregulated and downregulated DEGs (50 each) common in ESRD patient-derived monocytes
and ex vivo IS-treated monocytes. Common DEGs are listed according to a log2 fold change (p < 0.05,
FDR < 0.25).






16967771 CXCL8 C-X-C motif chemokine ligand 8 6.5945 0.3171
17000793 CD14 CD14 molecule 6.1733 0.3099
17058719 NCF1C neutrophil cytosolic factor 1C pseudogene 4.9855 0.7591
16716590 MYOF myoferlin 4.7301 0.3701
16857736 MCEMP1 mast cell expressed membrane protein 1 4.5776 0.6207
16854486 DSC2 desmocollin 2 4.4608 0.3290
16952874 CCR1 C-C motif chemokine receptor 1 4.3715 0.3022
16869666 ADGRE3 adhesion G protein-coupled receptor E3 4.2049 0.7200
16891082 CYP27A1 cytochrome P450 family 27 subfamily Amember 1 4.0764 1.2708
16709333 TCF7L2 transcription factor 7 like 2 3.9883 0.9611
16684056 FGR FGR proto-oncogene, Src family tyrosinekinase 3.8943 0.4057
16768297 DUSP6 dual specificity phosphatase 6 3.8745 0.3807
17086496 DAPK1 death associated protein kinase 1 3.8445 0.4779
17059955 PDK4 pyruvate dehydrogenase kinase 4 3.5273 0.4756
17096030 FBP1 fructose-bisphosphatase 1 3.4529 0.4545
17046911 NCF1B neutrophil cytosolic factor 1B pseudogene 3.3574 1.0349
16896561 CYP1B1 cytochrome P450 family 1 subfamily Bmember 1 3.2051 1.5738
16684144 PTAFR platelet activating factor receptor 3.1942 0.3886
17000724 HBEGF heparin binding EGF like growth factor 2.8582 0.8480
17044442 SNX10 sorting nexin 10 2.8334 0.3116
16732985 SLC37A2 solute carrier family 37 member 2 2.7402 0.3424
16658864 PGD phospho-gluconate dehydrogenase 2.6875 0.7136
17111711 VSIG4 V-set and immunoglobulin domaincontaining 4 2.6333 0.6154
16805474 ARRDC4 arrestin domain containing 4 2.5744 0.3588
16777685 FLT3 fms related tyrosine kinase 3 2.5176 0.4135
17053697 LOC644090 uncharacterized LOC644090 2.4605 0.6179
16991125 NDST1 N-deacetylase and N-sulfotransferase 1 2.3802 0.3088
16669196 CD101 CD101 molecule 2.2198 0.5474
17063722 CLEC5A C-type lectin domain containing 5A 2.2079 0.6715
16875723 TMEM150B transmembrane protein 150B 2.1721 0.3627
16748788 MGST1 microsomal glutathione S-transferase 1 2.1668 0.8541
16867784 C3 complement C3 2.1475 0.5078
17121820 USP32 ubiquitin specific peptidase 32 2.1419 0.3092
16929920 H1F0 H1 histone family member 0 2.0673 0.3007
16848070 SLC16A6 solute carrier family 16 member 6 2.0182 0.4231
16839524 MIR22HG MIR22 host gene 2.0173 0.4588
16774427 LACC1 laccase domain containing 1 1.9373 0.7574
16729298 ACER3 alkaline ceramidase 3 1.9074 0.4178
16894335 ADAM17 ADAM metallopeptidase domain 17 1.9073 0.3308
17026267 TNF tumor necrosis factor 1.8353 0.6968
17013520 SASH1 SAM and SH3 domain containing 1 1.8301 0.6865
17115636 G6PD glucose-6-phosphate dehydrogenase 1.8165 0.4642
16683445 FUCA1 alpha-L-fucosidase 1 1.7958 1.5007
16876849 ASAP2 ArfGAP with SH3 domain, ankyrin repeatand PH domain 2 1.7922 0.3036
16852871 SERPINB2 serpin family B member 2 1.7359 2.2714
17058978 GSAP gamma-secretase activating protein 1.7231 0.3256
17071162 CPQ carboxypeptidase Q 1.7211 0.3579
16968447 GPAT3 glycerol-3-phosphate acyltransferase 3 1.7197 0.3522
16720318 TALDO1 trans-aldolase 1 1.6930 0.3785
16688929 GNG5 G protein subunit gamma 5 1.6846 0.3409
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16781893 YME1L1 YME1 like 1 ATPase −5.1212 −0.3594
16798132 SNORD116-1 small nucleolar RNA, C/D box 116-1 −4.8499 −0.8151
17074313 DEFA1B defensin alpha 1B −4.7542 −0.3063
16761201 CD69 CD69 molecule −4.1940 −0.3732
16781830 TRAJ17 T cell receptor alpha joining 17 −3.9577 −0.3544
16877297 TRIB2 tribbles pseudo-kinase 2 −3.6828 −0.3169
16906571 STAT4 signal transducer and activator oftranscription 4 −3.6785 −0.3412
16798206 SNORD116-20 small nucleolar RNA, C/D box 116-20 −3.3709 −0.3708
16672669 LY9 lymphocyte antigen 9 −3.2701 −0.3066
16748205 CLEC2D C-type lectin domain family 2 member D −3.2426 −0.3819
16761631 DUSP16 dual specificity phosphatase 16 −3.1818 −0.4038
17110670 PIM2 Pim-2 proto-oncogene, serine/threoninekinase −2.9802 −0.6422
16912130 CST7 cystatin F −2.5494 −0.3388
17092767 MLLT3 MLLT3, super elongation complex subunit −2.4775 −0.7344
16720085 IFITM1 interferon induced transmembrane protein1 −2.4475 −0.3137
17056849 TRGV3 T cell receptor gamma variable 3 −2.4407 −0.8184
17005858 HIST1H2AI histone cluster 1 H2A family member i −2.2799 −0.4418
16995717 SNORD72 small nucleolar RNA, C/D box 72 −2.2604 −0.7078
17016503 HIST1H3I histone cluster 1 H3 family member i −2.2455 −0.4036
16764564 LIMA1 LIM domain and actin binding 1 −2.2305 −0.3310
16934045 PIK3IP1 phosphoinositide-3-kinase interactingprotein 1 −2.2022 −0.4481
16900737 ANKRD36B ankyrin repeat domain 36B −2.0806 −0.3064
17016386 HIST1H3D histone cluster 1 H3 family member d −2.0589 −0.3624
17122454 ANKRD36 ankyrin repeat domain 36 −2.0333 −0.5181
17121094 SRP54-AS1 SRP54 antisense RNA 1 (head to head) −1.9509 −0.4420
16756286 C12orf75 chromosome 12 open reading frame 75 −1.8645 −0.3758
16798248 SNHG14 small nucleolar RNA host gene 14 −1.8228 −0.3124
17122912 ANKRD20A5P ankyrin repeat domain 20 family memberA5, pseudogene −1.8010 −0.3463
16686060 SLC2A1 solute carrier family 2 member 1 −1.7904 −0.3997
16968314 PRDM8 PR/SET domain 8 −1.7855 −0.5214
17016383 HIST1H4D histone cluster 1 H4 family member d −1.7560 −0.3952
16837296 ARHGAP27P2 Rho GTPase activating protein 27pseudogene 2 −1.7467 −0.4159
17005560 HIST1H4C histone cluster 1 H4 family member c −1.7216 −0.3526
16849349 TNRC6C-AS1 TNRC6C antisense RNA 1 −1.6941 −0.6821
17016360 HIST1H4B histone cluster 1 H4 family member b −1.6893 −0.5007
17011708 SLC16A10 solute carrier family 16 member 10 −1.6648 −0.4770
16780585 GPR18 G protein-coupled receptor 18 −1.6552 −0.4941
17116745 P2RY8 P2Y receptor family member 8 −1.6285 −0.4951
16987361 ARSK arylsulfatase family member K −1.6196 −0.3051
16869324 PRDX2 peroxiredoxin 2 −1.6134 −0.4093
16980528 LRBA LPS responsive beige-like anchor protein −1.6071 −0.3149
16838300 TMC8 transmembrane channel like 8 −1.5657 −0.3583
17100888 LOC102723630 uncharacterized LOC102723630 −1.5554 −0.4080
16956983 CBLB Cbl proto-oncogene B −1.5203 −0.5545
16930173 APOBEC3D apolipoprotein B mRNA editing enzymecatalytic subunit 3D −1.5054 −0.4054
16985518 PIK3R1 phosphoinositide-3-kinase regulatorysubunit 1 −1.5016 −0.5210
17113606 septin 6 septin 6 −1.5012 −0.4799
16993173 LOC728554 THO complex 3 pseudo-gene −1.4969 −0.3166
16889160 PLCL1 phospholipase C like 1 (inactive) −1.4891 −0.3684
17013197 PEX3 peroxisomal biogenesis factor 3 −1.4474 −0.3493
2.3. Principle Enriched Pathways in ESRD Patient-Derived Monocytes
To gain mechanistic insight into the genes found in our microarray analysis by identifying the
principle enriched pathways, gene set enrichment analysis (GSEA) was performed on DEGs in ESRD
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patient-derived monocytes using the Gene Set Enrichment Analysis (GSEA) Molecular Signatures
Database (MsigDB). This analysis is a computational method that detects modest, but coordinated,
changes in the expression of groups of functionally related genes [26]. We first ranked all genes according
to the extent of their differential expression in monocytes derived from ESRD patients and healthy
controls. We then computed normalized enrichment scores (NES) for a collection of 50 curated hallmark
gene sets representing canonical biological pathways, and identified gene sets overrepresented at both
extremes of the ranked list. As presented in Figure 3A, there were 35 significantly enriched pathways
obtained from 6630 DEGs in monocytes derived from ESRD patients (p < 0.05 and FDR < 0.25) (Figure 3A
and Table S3). Immune response-related GSEA pathways such as IFN-γ response, IL-6/JAK/STAT3
signaling, inflammatory response, and TNF-α signaling via NF-κB were included (Figure 3A,B). Of note,
the top 10 enriched pathways incorporated major metabolic pathways such as glycolysis, oxidative
phosphorylation, cholesterol homeostasis, fatty acid metabolism, and mTORC1 signaling, suggesting
that metabolic alterations affect immune functions in monocytes of ESRD patients (Figure 3A,C and
Figure S1A). Moreover, a pathway related to xenobiotic metabolism, specifically involved in removal
of xenobiotics via cytochrome p450, was enriched in ESRD patient-derived monocytes (Figure 3A,D).
We generated GSEA enrichment plots and heatmaps of DEGs belonging to metabolic pathways and
inflammatory pathways enriched in monocytes derived from ESRD patients (Figure 3B–D and Figure S1).
We also identified the IS-induced notch signaling pathway, which was recently reported to mediate
vascular inflammation in CKD via Delta-like 4 (DII4) [17], as an enriched pathway (Figure 3A and
Figure S1B). Thus, this analysis revealed that metabolic pathways, including glycolysis and oxidative
phosphorylation, were the main pathways affected in ESRD patient-derived monocytes exposed to
uremic milieu.
2.4. Interaction Network Analysis of Common DEGs comparing ESRD Patient-Derived Monocytes and
IS-Treated Monocytes
We next constructed the interaction network between common upregulated or downregulated
DEGs in ESRD patient-derived monocytes and IS-treated monocytes via STRING and ClueGo analysis.
The physical or functional protein-protein interaction (PPI) network was constructed and visualized
using web-based STRING (Protein-Protein Interaction Networks Functional Enrichment Analysis)
software (Figure 4A and Figure S2A). In the PPI network of 148 commonly upregulated DEGs,
there were 35 protein nodes, which formed five distinct clusters with 28 edges under the application of
a highest confidence (0.900). The average node degree was 0.544, and the local clustering coefficient
average was 0.191 (Figure 4A, unconnected nodes hidden); whereas 139 common DEGs downregulated
in ESRD patient-derived monocytes and IS-treated monocytes were separated into three distinct
networks with 17 protein nodes (Figure S2A, unconnected nodes hidden). The networks analyzed with
148 commonly upregulated DEGs consisted of 150 significantly enriched gene ontology (GO) biological
processes (FDR < 0.05). Of these, GO terms describing response to stimuli and metabolic processes
related to 86 and 92 genes, respectively (data not shown). TNF-α, CXCL8, CCR1, and C3 were closely
interconnected and each of their networks was further expanded by additional proteins (Figure 4A).
Of interest, a STRING-generated interaction network revealed three genes, G6PD, PGD and TALDO1,
involved in pentose biosynthetic processes were significantly enriched and strongly associated with
each other in monocytes derived from ESRD patients and IS-treated monocytes (Figure 4A, red circle).
In contrast, analysis of commonly downregulated DEGs revealed 15 significantly enriched GO biological
process (FDR < 0.05), including chromatin silencing and chromatin organization-associated gene sets
with 9 and 12 genes, respectively (Figure S2A and data not shown), implying that the expression
of many metabolic and inflammatory genes may be increased. To further decipher functionally
grouped gene ontology and pathway annotation networks, we also conducted ClueGo analysis
allowing the visualization of terms corresponding to a list of genes and for comparing functional
annotations of two clusters (Figure 4B). As observed in GSEA and STRING analysis (Figures 3 and
4A), the pentose phosphate pathway (PPP) and AhR-associated pathway were identified with ClueGo
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analysis (Figure 4B, blue rectangle). In addition, the superoxide generating nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase activator activity was also identified as a major pathway
(Figure 4B, red rectangle). To evaluate our results, enriched GO terms were investigated. Enrichment
scores were higher in phagosome (19.44%), PPP (19.44%), nuclear receptor meta-pathway (11.11%),
and NADPH oxidase activator activity (8.33%) (Figure 4C), as seen in our previous analysis. Further,
ClueGo analysis of 139 downregulated DEGs revealed the importance of histone modification-related
pathways (94.44%; Figure S2B,C). Taken together, STRING and ClueGO analysis illustrates that IS is a
major uremic toxin responsible for inducing a variety of genes related to metabolic pathways, the AhR
nuclear receptor pathway, and inflammatory pathways in ESRD patient-derived monocytes.
Figure 3. Gene set enrichment analysis (GSEA) of DEGs in ESRD patient-derived monocytes. (A), The 35
enriched pathways obtained from 6630 DEGs in monocytes of ESRD patients are listed (p < 0.05,
FDR < 0.25). (B–D), GESA plots of selected immune response-related pathways (B), metabolic pathways
(C), and xenobiotic metabolism pathway (D) are shown in monocytes from ESRD patients vs. healthy
controls. Left panels show GSEA enrichment plots (score curves) and the heatmap on the right
side of each panel is a visualization of the genes contributing the most to the enriched pathway or
biological process.
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2.5. Experimental Validation of DEGs in IS-Treated Monocytes
By analyzing shared DEGs between ESRD patient-derived monocytes and IS-treated monocytes we
have shown that genes in metabolic and AhR pathways are similarly regulated and interconnected. Next,
we performed functional and GO annotation analyses using DAVID functional annotation and KEGG
mapping to confirm distinct enrichment of a range of genes in several GO categories based on common
upregulated DEGs in IS-treated monocytes and ESRD patient monocytes. As described in STRING
and ClueGo analysis (Figure 4 and Figure S2), metabolic pathways including the carbon pathway,
PPP, and glutathione metabolism (19 genes), phagosome (seven genes), cytokine-cytokine receptor
interaction (six genes), NF-κB signaling (four genes), TNF signaling (two genes), and metabolism
of xenobiotics by cytochrome p450 (two genes) were enriched GO terms in DEGs common between
IS-stimulated and ESRD patient-derived monocytes (Figure 5A, and Table S4). Major genes associated
with these pathways are listed in Figure 5A. To confirm expression of selected DEGs, we examined
mRNA expression of a total of 10 genes listed in Figure 5A using IS-treated monocytes, which were
obtained from independent HCs. The mRNA expression of CYP27A1, ME1, PGD, XYLT1, G6PD,
and TALDO1 (associated with metabolic pathways) was significantly upregulated compared to control
monocytes (Figure 5B). Especially, the mRNA expression of PPP-related genes such as G6PD, PGD,
and TALDO1, were increased by IS treatment in a dose-dependent manner (Figure S3A–C) and as
early as 4 h after stimulation (Figure S3D–F). TNF-α and MMP14 (related to TNF signaling) and
CYP1B1 and MGST1 (involved in xenobiotic metabolism) were markedly increased by IS treatment of
monocytes. These findings demonstrate that IS is responsible for changes in expression of genes in
the metabolic and inflammatory-related pathways, which are the major pathways altered in ESRD
patient-derived monocytes.
Figure 4. Cont.
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Figure 4. GO analysis of protein-protein interaction (PPI) networks for commonly upregulated DEGs
in ESRD patient-derived monocytes and ex vivo IS-stimulated monocytes. (A), STRING analysis
(Ver. 11.0) showing the predicted protein–protein interaction (PPI) networks among 148 selected
upregulated monocyte genes. The average node degree was 0.544 and the local clustering coefficient
average was 0.191. The network nodes represent each protein, while edges represent pair-wise protein
interactions, and line thickness indicates the strength of data support. Each node color represents
a specific biomolecular pathway. Red circles indicated genes related to PPP. (B), ClueGO analysis
of IS-related biological pathways in monocytes of ESRD patients. Functionally grouped network of
enriched categories was visualized by Cytoscape Plugin using 148 upregulated DEGs in Figure 2.
Each node is a gene ontology (GO) biomolecular pathway and the edges show connectivity between
nodes with regard to the functional linkage of biological processes. The node size represents the term
enrichment significance. Color code represents the statistical significance, where darker colors indicate
higher significance of the GO group. Blue rectangles indicate the pentose phosphate metabolism
and AhR pathways, and red rectangles represent NADPH oxidase activity. (C), The node pie chart
represents the molecular function of shared upregulated DEGs. Enrichment score (%) indicates the
upregulated DEGs involved in enriched Go biological processes. * p < 0.05, **, p < 0.01 indicates the
significant terms in the group.
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3. Discussion
In the present study, we found that IS, but not PCS, leads to marked alteration of gene expression
in monocytes from HCs and among these differentially expressed genes (DEGs), 287 were shared with
DEGs in ESRD patient-derived monocytes. Principle enriched pathways and interaction network
analysis of DEGs demonstrated that several metabolic pathways, such as the pentose phosphate
pathway, are primarily influenced by IS-rich uremic milieu in ESRD patient-derived monocytes.
These findings were validated in ex vivo IS-stimulated monocytes where increased mRNA expression of
Glucose-6-phosphate dehydrogenase (G6PD), phospho-gluconate dehydrogenase (PGD), trans-aldolase
1 (TALDO1), CYP1B1, and microsomal glutathione S-transferase 1 (MGST1) was found. Our findings
suggest that IS contributes to altered metabolic pathways in monocytes of ESRD patients, and thus,
these altered genes and pathways may be critical targets for modulating inflammatory responses of
monocytes in CKD patients.
Cardiovascular disease (CVD) is a highly common complication and the major cause of death
in patients with end-stage renal disease (ESRD) [6]. Several mechanisms have been proposed for the
heightened risk for CVD in CKD, including infiltration of monocytes into arteries, increased cytokine
production, and endothelial dysfunction [15,23]. Among over 100 uremic toxins identified, IS and
PCS have been extensively investigated as the main uremic toxins involved in the progression of
CVD [27–29]. Both IS and PCS are difficult to eliminate via classical dialysis approaches due to their
strong protein-binding capabilities [27,30]. Moreover, both play a pivotal role in the pathogenesis of
CVD through endothelial dysfunction, recruitment of leukocytes due to increased adhesion molecules
such as VCAM-1, and reactive oxygen species (ROS) production [31,32]. The majority of studies have
focused primarily on the adverse effects of IS and PCS on renal tissue, endothelial cells, and skeletal
muscle cells [14,23,33]. Despite a key role of monocytes in the pathogenesis of CVD, the impact of IS
and PCS on immune cells in patients with CKD remains elusive [13,16,17,34].
To identify potentially pathogenic biological pathways associated with major uremic toxins in
monocytes of patients with CKD, we initially compared transcriptomic profiling between monocytes
derived from ESRD patients and ex vivo IS- or PCS-stimulated monocytes from HCs. A total of
6630 genes were identified as differentially expressed genes (DEGs) in ESRD patient-derived monocytes
compared to cells from HCs, whereas the number of DEGs was markedly smaller in IS- and PCS-treated
monocytes (1599 and 270 genes, respectively; Figures 1 and 2). Thus, this implies that a variety of
uremic toxins besides IS and PCS can also directly or indirectly influence gene expression in monocytes
during ESRD despite the crucial pathogenic roles of IS and PCS as major uremic toxins. Additionally,
it is possible that chronic exposure to uremic toxin results in more profound changes in the gene
profile of monocytes in ESRD patients. A comparative analysis of common DEGs using Venn diagrams
suggests that alteration of gene expression in ESRD patient-derived monocytes is more associated with
the effect of IS (287 genes) than with PCS (25 genes) (Figure 2). Our previous study demonstrated
that, in contrast to IS, PCS does not induce production of TNF-α or IL-6 proinflammatory cytokines in
human monocytes [16]. However, similar to IS, the concentration of PCS in serum of CKD patients has
been reported to be associated with CVD complication in CKD [24] and a few studies have reported that
PCS regulates the expression of TNF-α, MCP-1, and adhesion molecules, as well as ROS production in
endothelial cells and macrophages, resulting in CVD in mice [13,35]. In contrast, consistent with our
previous report, in the present study ex vivo PCS-stimulated human monocytes were not largely found
to reflect the transcript profile of monocytes in patients with ESRD. Furthermore, IS led to mRNA
induction of TNF-α and IL-1β in a dose-dependent manner (50~1000 µM) as depicted in previous
report [16]. However, PCS had a minimal effect on mRNA induction of TNF-α and IL-1β at all doses
(250~1000 µM) (Figure S4A,B). Therefore, we focused on the genes regulated by IS in ESRD patients.
Functional GSEA of monocytes from patients with ESRD identified the alteration of major
metabolic pathways including glycolysis, oxidative phosphorylation, and fatty acid metabolism,
as well as immune response-related pathways such as interferon-α and γ responses, the inflammatory
response, and TNF-α signaling via NF-κB (Figure 3 and Table S3). We and others have demonstrated
Toxins 2020, 12, 621 15 of 22
that IS elicits immune responses by its binding to AhR in monocytes/macrophages [36,37]. Thus,
identification of immune response-related pathways in GSEA was expected. Furthermore, the notch
signaling pathway was also identified in our GSEA (Figure S1B), which aligns with a recent study in
which crosstalk between OATP2B1 and Dll4-Notch signaling in macrophages was found to mediate
IS-induced vascular inflammation in CKD [17]. Of interest, a number of metabolic pathways were
selected with higher NES (normal enrichment score) (Figure 3A and Table S3), suggesting that metabolic
reprogramming of monocytes is induced when they are exposed to uremic milieu and is perhaps
linked to inflammatory regulation in monocytes of ESRD patients. An increasing body of evidence
demonstrates that activated monocytes/macrophages strictly modulate their metabolic programs
to meet the demands of participation in immune responses such as cytokine production, and that
metabolites play important roles in epigenetic modifications [38–40]. Much focus recently has been
on understanding the interconnection between metabolic reprogramming and immune function for
discovering important therapeutic targets in many inflammatory disorders [40–43]. In diabetic CKD
patients, systemic metabolic failure induced by obesity, insulin resistance, and β-cell dysfunction
exacerbates the progression of renal disease [44]. IS-mediated metabolic alterations in skeletal muscle
also induce uremic sarcopenia in CKD [45]. However, little is known about metabolic alteration of
immune cells in ESRD patients.
Network analysis using STRING software revealed five predicted protein-protein interaction
(PPI) networks from commonly upregulated DEGs between ESRD patient-derived monocytes and
IS-stimulated monocytes under stringent conditions. Among 35 selected protein nodes, TNF-α,
CXCL8, CCR1, and C3 were found to be interconnected and each of their networks was further
expanded by additional proteins (Figure 4A). Several studies have demonstrated that an increase
in TNF-α in the uremic milieu is involved in renal dysfunction [46]. TNF-α is also considered an
important pro-atherogenic cytokine in CVD [47]. In addition, IS is a potent endogenous ligand for
AhR, and IS-stimulation of monocytes/macrophages results in increased production of TNF-α through
a complicated regulation mechanism between AhR, NF-κB, and SOCS2 [16,36]. Chemokines and
their receptors regulate migration of leukocytes under normal and inflammatory conditions. CXCL8
is secreted by activated monocytes and potently attracts neutrophils to inflamed sites [48], whereas
expression of CCR1 on monocytes is increased during macrophage differentiation and is also critical for
their recruitment to sites of inflammation [49]. Although most components of the complement system
are produced by hepatocytes, a variety of innate cells, including stimulated monocytes and macrophages,
are extrahepatic producers of complement proteins, such as C3, suggesting its local or intracellular
role in immune responses [50]. Given the pivotal role of inflammatory monocytes/macrophages
for pathogenesis of CVD, IS-mediated alteration of gene expression in monocytes may favor their
infiltration into vessels, differentiation into macrophages, and local activation in CKD [51,52].
In addition, the interaction network generated by STRING and ClueGo analysis revealed the
pentose biosynthetic process as a commonly enriched pathway (Figure 4A, red circle and Figure 4B,
blue rectangle). Our confirmatory qPCR assay showed that the expression of G6PD, PGD, and TALDO1
genes of the pentose biosynthetic process is significantly increased in IS-treated monocytes from
independent HCs (Figure 5). PPP is a metabolic pathway parallel to glycolysis. However, PPP does
not produce or use energy in the form of ATP [53]. It has been demonstrated that LPS-stimulated
macrophages upregulate the activity of PPP, supplying precursors for nucleotide synthesis and
nicotinamide adenine dinucleotide phosphate (NADPH), which is used for reactive oxygen species
(ROS) production by NADPH oxidase, fatty acid synthesis, and anti-oxidant cellular defense [54].
Sato et al. recently reported that IS induces metabolic alterations, such as upregulation of glycolysis
with PPP acceleration, as an anti-oxidative stress response in skeletal muscle cells. This alteration
induces uremic sarcopenia through downregulation of the TCA cycle, mitochondrial damage, and ATP
shortage [45], suggesting that IS has the ability to alter metabolic pathways. In agreement with our
findings, a single-cell analysis of PBMCs in ESRD illustrated major changes in the metabolic pathways
of CD14+ monocytes [18].
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The present study has several limitations. First, all microarray and ex vivo experiments were
conducted in the culture media supplemented with 10% FBS but not with human albumin despite IS
and PCS being mainly bind to albumin in vivo [55]. Thus, it is possible that the concentration of IS is at
supraphysiological level. Additionally, no potassium adjustments were performed for the controls
even though IS is a potassium salt [56]. These points must be carefully considered in understanding
our findings. Second, circulating monocytes of ESRD patients are chronically exposed to various
uremic toxins, while our microarray study was designed to induce an acute reaction to exposure to
a specific uremic toxin such as IS and PCS for a short period of 24 h. Thus, we cannot rule out the
possibility that a part of the gene expression changes affected by IS was identified. Given a short
circulating lifespan (mean 1.0 ± 0.26 day) of classical CD14+ monocytes in vivo [57] and a technical
difficulty of maintaining monocytes without differentiation into macrophages for more than at least
24 h ex vivo, IS-mediated changes in gene expression in peripheral monocytes would have been
evaluated in the present study. Future studies are required to investigate the long-term effect of IS
on the differentiation program and gene expression profiling of macrophages utilizing transcriptome
analysis. Finally, the concentrations of IS and PCS differed in initial microarray experiments. In fact,
the concentrations we used were determined based on our previously published report, showing that
IS has more a potent effect on induction of TNF-α mRNA in monocytes compared with PCS [16]. In the
present study, we also found that IS led to mRNA induction of TNF-α and IL-1β in a dose-dependent
manner (50~1000 µM), whereas PCS had a minimal effect on mRNA induction of TNF-α and IL-1β at
all doses (250~1000 µM) (Figure S4A,B). It would have been better to use the same concentration of IS
and PCS in the microarray study. However, it is likely that the transcriptome analysis of monocytes
treated even with the concentration of IS and PCS we used in this study is meaningful based on the
above reasons.
In summary, the current study provides new insight into IS-mediated alteration of gene expression
and biological pathways in ESRD patient-derived monocytes via analysis of their transcriptome by
microarray. IS primarily contributes to metabolic reprograming including upregulated activity of PPP
and changes in AhR and inflammatory signaling in monocytes of ESRD patients. Our data suggest
that these altered genes and pathways may be critical targets for modulating inflammatory responses
of monocytes, which are key players in the pathogenesis of CVD in CKD patients.
4. Materials and Methods
4.1. Peripheral Blood Mononuclear Cell (PBMC) Isolation
The study protocols were reviewed and approved by the institutional review board of Seoul
National University Hospital and Severance Hospital, Korea. Peripheral blood of ESRD patients and
healthy controls (HCs) was drawn after obtaining written, informed consent. The methods were
performed in accordance with the approved guidelines (IRB No.1403-049-564 for Seoul National
University Hospital, Date: 31 March 2014 and IRB No. 4-2013-0581 for Severance Hospital, Date:
10 October 2013). Mononuclear cells were isolated from peripheral blood by density gradient
centrifugation using Bicoll separating solution (BIOCHROM Inc, Cambridge, UK).
4.2. Sample Preparation for Microarray
Isolation of monocytes from PBMCs of three HCs and three ESRD patients between the ages of
50 and 75 were performed through a positive selection using anti-CD14 magnetic beads (Miltenyi
Biotec, Bergish, Gladbach, Germany). The demographic characteristics of ESRD patients enrolled in
microarray analysis are summarized in Table S1. Monocytes for ex vivo approaches were separated
from PBMC of three healthy subjects through negative selection using pan-monocyte microbeads
(Miltenyi Biotec Inc, Auburn, CA, USA), then further treated with IS (1000 µM) or PCS (500 µM) for
24 h in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin,
100 µg/mL streptomycin, and 2 mM L-glutamine. Total RNA from all samples was prepared using an
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RNA purification kit (Qiagen) and checked for integrity and purity by OD 260/280 ratio on the Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
4.3. Microarray Gene Expression Analysis
The Affymetrix Whole transcript (WT) Expression array process was conducted with reference
to the instructions provided by the manufacturer (GeneChip Whole Transcript PLUS reagent Kit,
ThermoFisher scientific, Waltham, MA, USA). cDNAs were synthesized using the GeneChip WT
Amplification kit, followed by cDNA fragmentation. Consecutively, fragmented cDNAs were
biotin-labelled with terminal deoxynucleotidyl tranferase (TdT) using the GeneChip WT Terminal
labelling kit. Approximately 5.5 µg of labelled DNA targets was hybridized into the Affymetrix
GeneChip Human 2.0 ST Array at 45 ◦C for 16 h. Hybridized arrays were then washed and stained
on the GeneChip Fluidics Station 450 and scanned on a GCS3000 Scanner (Affymetrix, ThermoFisher
scientific, Waltham, MA, USA). Measured signal values were computed using the Affymetrix®
GeneChip™ Command Console software. Raw data of microarray have been deposited in the NCBI
Gene Expression Omnibus (accession code GSE155325 and GSE155326).
4.4. Data Preparation and Descriptive Statistics
The microarray represents approximately 40,716 human genes. Raw data were obtained
automatically with reference to the Affymetrix data extraction protocol using the software provided by
Affymetrix GeneChip® Command Console® Software (AGCC). Data were summarized and normalized
with Robust Multi-array Average (RMA) method provided by Affymetrix® Expression Console™
Software (EC) (ThermoFisher scientific, Waltham, MA, USA) or the R-package Oligo (ver. 1.52.0) [58]
and limma (ver. 3.44.3) [59]. We obtained the data using gene-level RMA analysis and differentially
expressed gene (DEG) analysis. The comparative analysis was carried out using T-test. Moreover,
false discovery rate (FDR) was controlled by adjusting p-value via Benjamini-Hochberg algorithm.
For DEG sets, hierarchical cluster analysis was conducted using the complete linkage with Euclidean
distance as a measure of similarities between DEG sets. All statistical tests and visualization of DEGs
were conducted using R statistical language v. 3.6.2. (www.r-project.org) [60].
4.5. Gene Expression Profiling and Analysis
Genes were selected based on p-value of 0.05 or less and corrected through Benjamin and Hochberg
multiple testing (a false discovery rate) of 25% (FDR = 0.25). Selected data were then applied to
hierarchical cluster analysis to display basal and luminal differences. These data were further filtered
according to gene expression levels with a log2 fold change of <−0.3 and >0.3. Collected microarray
data of common genes between ESRD and IS were visualized with heatmap using the pheatmap
R package (https://rdrr.io/cran/pheatmap) [61].
4.6. Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA) [26,62] was used to examine the significantly-enriched
pathways with the normalized microarray dataset of the ESRD/HC group to various gene sets in the
GSEA Molecular Signatures Database (MsigDB). All transcripts within annotated genes (~31,727 features
in total) regarding expression values were uploaded to a locally-installed GSEA tool and compared
with the catalog H (50 human gene sets) [63]. The reported GSEA outputs were filtered based on a
normalized enrichment score (NES) > 1.3.
4.7. GO and Protein Pathway Analysis
Protein pathways associated with commonly expressed genes were examined by STRING analysis
(https://string-db.org/). Protein–protein, direct (physical) or indirect (functional) interactions (highest
confidence: 0.900) were critically assessed based on STRING data base. The intensity of edges reflects
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the degree of interaction score of gene/protein interaction. Additionally, each group of proteins
associated with particular biological pathways are presented by different colors representing the
network nodes.
Furthermore, Gene-functionality grouped networks were visualized by Cytoscape software
(https://cytoscape.org/index.html). Two plug-ins of Cytoscape, ClueGO (ver. 2.5.7) [64] and CluePedia
(ver. 1.5.7) [65] were used in the present study. The results of PPI network analysis are illustrated by
large clusters of genes which were classified into different functional groups on the basis of GO, KEGG,
Wiki Pathways, and Reactome.
4.8. Gene Functional Annotation and GO Annotation
Gene functional annotation and GO annotation were conducted by importing significant gene
sets into the Gene Functional Annotation Tool available at the DAVID (http://david.abcc.ncifcrf.gov/)
and KEGG Mapper websites (https://www.genome.jp/kegg/tool/map_pathway2.html) (p-value < 0.05).
4.9. Validation Microarray Genes-Quantitative RT-PCR
To validate common DEGs in ex vivo monocytes, PBMCs of HCs were separated and CD4 positive
monocytic cells were sorted. Then, these cells were treated with IS for 24 hr. Total RNA of all samples
was separated by using RNA purification kit (Macherey-Nagel GmbH & Co. KG, Düren, Germany)
followed by cDNA synthesis (Bio-line, London, UK). Subsequently, real-time quantitative RT-PCR
was performed through CFX system (Bio-Rad, Hercules, CA, USA) with SensiFAST SYBR® Lo-ROX
(Bio-line, London, UK). The primers used in this investigation were shown in Table S5. Normalization
of gene expression levels was based on the expression of ACTINB. In addition, the comparative CT
method (∆∆CT) was used for quantification of gene expression.
For data analysis, two-tailed paired student’s t-test were conducted using Graph Pad Prism
8 (GraphPad Software, La Jolla, CA, USA) and Microsoft Excel 2013. p < 0.05 was considered
statistically significant.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/12/10/621/s1,
Figure S1: Gene set enrichment analysis (GSEA) plot of mTORC1 signaling (A) and notch signaling (B) of 35
enriched pathways analyzed using 6630 DEGs in monocytes of ESRD patients (p < 0.05, FDR < 0.25). Left panels
are enrichment plots and right panels are heatmaps. Figure S2: GO Analysis of protein-protein interaction (PPI)
networks for DEGs commonly downregulated in both ESRD patient-derived monocytes and ex vivo IS-stimulated
monocytes of HCs. (A), STRING analysis derived from PPI networks for 139 selected downregulated monocyte
genes. The network nodes represent proteins while edges represent protein interactions and strength. The average
node degree was 0.673, and the local clustering coefficient average was 0.118. (B), ClueGO gene ontology analysis
of 139 shared downregulated DEGs. Colors represent the statistical significance, where darker color indicates
higher significance of GO group. Each node and edges show GO biomolecular pathways and the connectivity
between each node, respectively. (C). Go biological process pie chart of ClueGo analysis (B) Enrichment score (%)
indicates the upregulated DEGs involved in enriched Go biological processes. Figure S3: A dose-dependent effect
of IS on G6PD, PGD, and TALDO1 mRNA expression (A–C) and time-kinetics on expression of these genes (D–F)
in purified monocytes. Monocytes isolated from independent HCs (n = 4 or 5) were treated with IS at indicated
concentration for 24 h (A–C) or in indicated times (D–F), followed by RT-qPCR. Figure S4: IS or PCS-induced
mRNA expression of TNF-α (A) and IL-1β (B) in human monocytes. Monocytes isolated from independent HCs
(n = 4 or 5) were treated with IS or PCS in the indicated concentration for 24 h, followed by RT-qPCR. Table S1:
Baseline characteristics in study subjects. Table S2: Common upregulated (148) and downregulated (139) DEGs in
monocytes of ESRD patients and IS-treated monocytes. Common DEGs are listed according to a log2 fold value
(p < 0.05, FDR < 0.25). Table S3: Pathways (35) associated with DEGs in monocytes of patients with ESRD. These
pathways are listed based on FWER p-value (p < 0.05, FDR < 0.25). Table S4: The enriched pathways and their
associated genes in commonly upregulated DEGs in IS-treated monocytes and ESRD patient monocytes identified
via analysis of a DAVID functional annotation and KEGG mapper. This list was ordered based on a log2 fold
value of ESRD patients (p < 0.05, FDR < 0.25). Table S5: Primers for validated genes.
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